Reuters logo
BRIEF-Mithra Pharmaceuticals concludes exclusive license and supply agreement with Mayne Pharma for marketing of Myring in US
February 28, 2017 / 8:25 AM / in 9 months

BRIEF-Mithra Pharmaceuticals concludes exclusive license and supply agreement with Mayne Pharma for marketing of Myring in US

Feb 28 (Reuters) - Mithra Pharmaceuticals SA:

* Mithra concludes exclusive license and supply agreement with Mayne Pharma for myring marketing in the United States

* Under the terms of the agreement, Mayne Pharma will pay milestones of at least 10 million euros ($10.59 million) following approval by US (FDA)

* Mithra will produce Myring for Mayne Pharma in its Research, Development and Production Center (Mithra CDMO)

* Under the terms of the agreement, Mithra will receive 2.4 million euros upon signing Source text for Eikon: Further company coverage: ($1 = 0.9446 euros) (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below